Innovation in Veterinary mRNA Vaccines Takes the Lead! Healrna Wins 2025 CFS Financial Summit Annual Award

From July 16 to 17, 2025, the 14th CFS Financial Summit & 2025 New Quality Productivity Entrepreneurs Conference was grandly held in Shanghai. Established in 2012, the CFS Financial Summit is one of China's most influential thought leadership platforms in the economic sector. This year’s summit, themed "Navigating Waves of Change, Building Economic Resilience," attracted over 1,200 leaders from government, top-tier enterprises, and academia, with total platform engagement exceeding 30 million views.

Healrna stood out among numerous outstanding enterprises and was honored with the "2025 Outstanding Product Innovation Leadership Award" in recognition of its cutting-edge innovations and exceptional contributions in the field of veterinary mRNA vaccines.

This prestigious honor not only represents high recognition of Healrna's technological innovation capabilities, but also fully affirms its contributions to upgrading the biopharmaceutical industry. As a leader in mRNA technology, Healrna has always adhered to its mission of "driving health through technological innovation," establishing a comprehensive innovation system spanning from R&D to industrialization.

The company's independently developed veterinary mRNA vaccine series, with their advantages of high efficacy and safety, provide groundbreaking solutions for global livestock disease prevention and control.

Moving forward, Huiliao Bio will continue to deepen mRNA technology research, accelerate the transformation of innovative achievements, and expand international collaborations. Committed to becoming an innovation leader in global animal health, the company will contribute its expertise and strength to building a more resilient global public health system.

#About Healrna #

Healrna stands as the world's first industry leader to achieve full industrial chain deployment of innovative mRNA animal vaccines, revolutionizing the future of animal health protection. By assembling top global scientific talent—with a core team hailing from premier international pharmaceutical companies and authoritative research institutions—the company has established comprehensive proprietary technologies spanning from foundational sequence design and advanced delivery systems to large-scale production, setting new industry benchmarks.

Healrna possesses an end-to-end proprietary platform encompassing mRNA design, synthesis, delivery, and industrial-scale production. Its groundbreaking delivery system technology exponentially enhances vaccine efficacy while achieving a cost revolution for mRNA vaccines in livestock, spearheading industry trends in cost-efficiency.

The company’s R&D pipeline covers livestock, companion animals, and beyond, with pioneering breakthroughs in vaccines targeting porcine diarrhea-related viruses and feline infectious peritonitis (FIP). Driving industry transformation through mRNA technology, Huiliao Biotech is accelerating the global animal vaccine sector into a new era of precision medicine!